Mesothelioma

“ I am an experienced oncologist specializing in the diagnosis and management of mesothelioma. My focus is on achieving a prompt and accurate diagnosis, which is essential for guiding effective treatment. I am actively involved in the TLC Multidisciplinary Team (MDT), where I work closely with thoracic surgeons, radiologists, pathologists, and specialist nurses to develop individualized treatment plans tailored to each patient’s clinical needs and personal preferences.

“ Beyond clinical care, I am deeply committed to research and have contributed to numerous peer-reviewed publications in the field of mesothelioma. My research focuses on improving treatment strategies, exploring biomarker-driven therapies, and enhancing patient outcomes.

“ My approach is patient-centric, ensuring that patients and their families feel supported and well-informed throughout their journey. I take the time to explain treatment options and potential outcomes clearly, empowering patients to make informed decisions. My goal is to combine clinical expertise and research to deliver the best possible care for mesothelioma patients.

Mesothelioma

Mesothelioma, a rare and aggressive cancer primarily caused by asbestos exposure, presents significant treatment challenges. The disease, often diagnosed at an advanced stage, has historically been treated with a combination of surgery, chemotherapy, and radiation. Standard chemotherapy regimens, typically involving combination chemotherapy, aim to control tumor growth and alleviate symptoms. Surgery, such as pleurectomy/decortication or extrapleural pneumonectomy, may be considered for early-stage disease to remove affected tissues and improve patient quality of life.

Recent advances have been made through clinical trials, providing new hope for mesothelioma patients. Notably, the CheckMate 743 trial has been a landmark study in the treatment of mesothelioma. This trial evaluated the efficacy of an immune checkpoint inhibitor targeting PD-1, in combination with a CTLA-4 inhibitor, compared to standard chemotherapy. Results showed that the combination immunotherapy significantly improved overall survival and progression-free survival in patients with unresectable malignant pleural mesothelioma. This breakthrough underscores the growing role of immunotherapy in enhancing treatment outcomes for this challenging cancer.

Building on these advancements, the Evolve Meso clinical trial, led by Principal Investigator Dr. Papadatos-Pastos at University College London Hospitals (UCLH), is exploring novel treatment combinations.